Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1451P - Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer

Date

21 Oct 2023

Session

Poster session 20

Topics

Tumour Immunology;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Rafael Bach Mora

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

R. Bach Mora1, P. Rocha1, L. Masfarre Pinto1, N. Navarro Gorro1, A. Rossell1, S. Gonzalez2, X. Villanova1, M. Giner3, I. Sánchez3, M.A. GALINDO CAMPOS2, R. Del Rey-Vergara2, A. Iñañez2, A. Taus Garcia1, L. Moliner4, M. Hardy-Werbin1, S. Clavé3, B. Bellosillo Paricio3, A. Rovira2, J. Perera-Bel5, E. Arriola1

Author affiliations

  • 1 Medical Oncology Department, Hospital del Mar-CIBERONC, 08003 - Barcelona/ES
  • 2 Cancer Research Program, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), 08003 - Barcelona/ES
  • 3 Pathology Department, Hospital del Mar, 8003 - Barcelona/ES
  • 4 Medical Oncology, ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, 08907 - Hospitalet de Llobregat/ES
  • 5 Margenomics, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), 08003 - Barcelona/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1451P

Background

Immune checkpoint blockade (ICB) has significantly impacted the treatment landscape in non-small cell lung cancer (NSCLC). However, this benefit is restricted to a subset of patients. While these results are encouraging, it is crucial to identify those patients who benefit the most from ICB and those who are refractory. Here we investigate the potential utility of longitudinal serum proteomic profiling to identify predictive biomarkers.

Methods

We included 40 metastatic NSCLC patients who received ICB treatment at Hospital del Mar, Barcelona between 2017-2021. Patients were categorized as long-term responders (LTR, n=20) if they had maintained radiologic response for more than 2 years or non-responders (NR, n=20) if they had disease progression at first radiological evaluation. Serum protein levels were assessed longitudinally (before treatment, previous cycle 2) using the Olink® Explore 384 Oncology panel.

Results

LTR had a greater proportion of high PD-L1 expression (p=0.01). Analysis of baseline serum samples showed an increase in LTR of proteins levels related to apoptosis and autophagy (CASP8, ATG4A), TCR signaling pathway (STAT5B, CRACR2A) and myeloid differentiation (ZBTB16, ARG1) (p<0.05 for all proteins). Higher levels of proteins related to immunosuppression and tumorigenesis (PDCD1, TGFBR2, KLK4, KLK6) prior to the second cycle of ICB were associated with poorer response to ICB, with non-responders exhibiting significantly higher levels (p<0.05 for all). Gene set enrichment analysis showed that LTR had an increase in myeloid cell differentiation process, while higher levels of immunoregulatory interactions between lymphoid and non-lymphoid cells were observed in NR (p<0.001 for all).

Conclusions

Our findings suggest that patients with high levels of proteins related to apoptosis, autophagy, TCR signaling, and myeloid differentiation at baseline may identify LTR to ICB. Our study underscores the potential use of baseline and longitudinal assessment of serum proteomics as valuable tools for patient selection who are suitable candidates for ICB. Further studies are needed to validate these findings and establish their potential clinical utility.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

B. Bellosillo Paricio: Financial Interests, Personal, Research Grant: Thermo Fisher, Roche Diagnostics, Roche Pharma, AstraZeneca; Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Janssen, Novartis; Financial Interests, Personal, Speaker’s Bureau: Janssen, Merck-Serono, Novartis, Qiagen, Thermo Fisher, Pfizer, Bristol Myers Squibb. E. Arriola: Financial Interests, Personal, Advisory Board: Roche, Boehringer Ingelheim, Lilly; Financial Interests, Personal, Invited Speaker: Takeda, MSD, AstraZeneca, BMS, Thermo Fisher Scientific, Guardant Health, Pfizer; Financial Interests, Personal, Other, Co-founder: Trialing Health; Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.